Randomized trial: First-line treatment with infliximab vs. conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease 14 Jan, 2021 | 01:27h | UTC First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial – Gut